Cargando…

Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension

Objective: To prospectively examine the long-term safety of a cardiovascular health dietary supplement by assessing a comprehensive set of safety measures. Design: Single-arm, open-label study. Location: National University of Natural Medicine, Portland, OR. Subjects: Thirty adults with screening bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Jennifer Joan, Hanes, Douglas Allen, Corroon, Jamie, Taylor, Jan, Bradley, Ryan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389760/
https://www.ncbi.nlm.nih.gov/pubmed/30222364
http://dx.doi.org/10.1089/acm.2018.0311
_version_ 1783397997369884672
author Ryan, Jennifer Joan
Hanes, Douglas Allen
Corroon, Jamie
Taylor, Jan
Bradley, Ryan
author_facet Ryan, Jennifer Joan
Hanes, Douglas Allen
Corroon, Jamie
Taylor, Jan
Bradley, Ryan
author_sort Ryan, Jennifer Joan
collection PubMed
description Objective: To prospectively examine the long-term safety of a cardiovascular health dietary supplement by assessing a comprehensive set of safety measures. Design: Single-arm, open-label study. Location: National University of Natural Medicine, Portland, OR. Subjects: Thirty adults with screening blood pressure readings consistent with prehypertension or stage I hypertension. Intervention: One caplet per day of a dietary supplement for 6 months. The investigated herbal–mineral supplement contains several ingredients, most notably Rauwolfia serpentina. Outcome measures: Primary measures included b-type natriuretic peptide (NT-proBNP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), electrolytes, and the Patient Health Questionnaire (PHQ-9). Exploratory measures included physical vital signs, cholesterol levels, high-sensitivity cardiac troponin-I, cystatin C, endothelin, interleukin (IL)-6, IL-17a, tumor necrosis factor-α, high-sensitivity C-reactive protein, blood counts, and the Patient Reported Outcome Measure Information System (PROMIS) Sleep Disturbance Short Form 8b. Results: NT-proBNP, AST, ALT, eGFR, sodium, calcium, magnesium, PHQ-9 score, and the majority of exploratory measures did not change. However, serum potassium increased (p < 0.05), systolic blood pressure decreased (p < 0.0001), and diastolic blood pressure decreased (p < 0.0001). There were no serious adverse events, but 30% of participants withdrew citing potential side effects, most commonly nasal congestion or fatigue; most participants who reported nasal congestion also reported concomitant seasonal allergies. Adherence to the supplement was 90.9%. Conclusions: The findings of this study suggest that the investigated dietary supplement is safe for long-term use in adults with prehypertension and stage I hypertension. Additional results of this study, particularly the increase in serum potassium and decreases in systolic and diastolic blood pressure, are promising and suggest that future research on this dietary supplement, or its ingredients, should further explore effects on blood pressure and biologic mechanisms of action, which may involve potassium-sparing and diuretic effects.
format Online
Article
Text
id pubmed-6389760
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-63897602019-02-26 Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension Ryan, Jennifer Joan Hanes, Douglas Allen Corroon, Jamie Taylor, Jan Bradley, Ryan J Altern Complement Med Original Research Objective: To prospectively examine the long-term safety of a cardiovascular health dietary supplement by assessing a comprehensive set of safety measures. Design: Single-arm, open-label study. Location: National University of Natural Medicine, Portland, OR. Subjects: Thirty adults with screening blood pressure readings consistent with prehypertension or stage I hypertension. Intervention: One caplet per day of a dietary supplement for 6 months. The investigated herbal–mineral supplement contains several ingredients, most notably Rauwolfia serpentina. Outcome measures: Primary measures included b-type natriuretic peptide (NT-proBNP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), estimated glomerular filtration rate (eGFR), electrolytes, and the Patient Health Questionnaire (PHQ-9). Exploratory measures included physical vital signs, cholesterol levels, high-sensitivity cardiac troponin-I, cystatin C, endothelin, interleukin (IL)-6, IL-17a, tumor necrosis factor-α, high-sensitivity C-reactive protein, blood counts, and the Patient Reported Outcome Measure Information System (PROMIS) Sleep Disturbance Short Form 8b. Results: NT-proBNP, AST, ALT, eGFR, sodium, calcium, magnesium, PHQ-9 score, and the majority of exploratory measures did not change. However, serum potassium increased (p < 0.05), systolic blood pressure decreased (p < 0.0001), and diastolic blood pressure decreased (p < 0.0001). There were no serious adverse events, but 30% of participants withdrew citing potential side effects, most commonly nasal congestion or fatigue; most participants who reported nasal congestion also reported concomitant seasonal allergies. Adherence to the supplement was 90.9%. Conclusions: The findings of this study suggest that the investigated dietary supplement is safe for long-term use in adults with prehypertension and stage I hypertension. Additional results of this study, particularly the increase in serum potassium and decreases in systolic and diastolic blood pressure, are promising and suggest that future research on this dietary supplement, or its ingredients, should further explore effects on blood pressure and biologic mechanisms of action, which may involve potassium-sparing and diuretic effects. Mary Ann Liebert, Inc., publishers 2019-02-01 2019-02-15 /pmc/articles/PMC6389760/ /pubmed/30222364 http://dx.doi.org/10.1089/acm.2018.0311 Text en © Jennifer Joan Ryan et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Ryan, Jennifer Joan
Hanes, Douglas Allen
Corroon, Jamie
Taylor, Jan
Bradley, Ryan
Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title_full Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title_fullStr Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title_full_unstemmed Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title_short Prospective Safety Evaluation of a Cardiovascular Health Dietary Supplement in Adults with Prehypertension and Stage I Hypertension
title_sort prospective safety evaluation of a cardiovascular health dietary supplement in adults with prehypertension and stage i hypertension
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389760/
https://www.ncbi.nlm.nih.gov/pubmed/30222364
http://dx.doi.org/10.1089/acm.2018.0311
work_keys_str_mv AT ryanjenniferjoan prospectivesafetyevaluationofacardiovascularhealthdietarysupplementinadultswithprehypertensionandstageihypertension
AT hanesdouglasallen prospectivesafetyevaluationofacardiovascularhealthdietarysupplementinadultswithprehypertensionandstageihypertension
AT corroonjamie prospectivesafetyevaluationofacardiovascularhealthdietarysupplementinadultswithprehypertensionandstageihypertension
AT taylorjan prospectivesafetyevaluationofacardiovascularhealthdietarysupplementinadultswithprehypertensionandstageihypertension
AT bradleyryan prospectivesafetyevaluationofacardiovascularhealthdietarysupplementinadultswithprehypertensionandstageihypertension